Literature DB >> 11102425

The in vitro activity of ABT773, a new ketolide antimicrobial agent.

J M Andrews1, T M Weller, J P Ashby, R M Walker, R Wise.   

Abstract

The in vitro activity of ABT773, a ketolide antimicrobial agent, was investigated and compared with those of seven other antibiotics. Type strains and 733 Gram-positive, Gram-negative and anaerobic isolates of clinical origin and four CHLAMYDIA: isolates were used. The activity of ABT773 was very similar to that of telithromycin, the other ketolide tested. The MIC(90) was < or = 0.5 mg/L for all bacteria examined except methicillin-resistant Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Haemophilus influenzae and BACTEROIDES: spp. The antichlamydial activity of ABT773 was greater than that of telithromycin, erythromycin and ciprofloxacin. Neither an increase in the size of the inoculm nor the addition of human serum had any marked affect on the in vitro activity of ABT773.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11102425     DOI: 10.1093/jac/46.6.1017

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  In vitro activity of the ketolide ABT-773.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

2.  Activities of ABT-773 against microaerophilic and fastidious organisms.

Authors:  Sydney M Finegold; Denise Molitoris; V T Phan; M-L Vaisanen; Hannah M Wexler
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 3.  Ketolides in the treatment of community-acquired respiratory tract infections: A review.

Authors:  Martin S Lipsky
Journal:  Curr Ther Res Clin Exp       Date:  2005-05

4.  In vitro activities of ABT-773, a new ketolide, against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.

Authors:  E J Goldstein; G Conrads; D M Citron; C V Merriam; Y Warren; K Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

5.  Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000.

Authors:  Donald E Low; Joyce de Azavedo; Karl Weiss; Tony Mazzulli; Magdalena Kuhn; Deirdre Church; Kevin Forward; George Zhanel; Andrew Simor; A McGeer
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 6.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 7.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection.

Authors:  Ana María Ríos; Asunción Mejías; Susana Chávez-Bueno; Mónica Fonseca-Aten; Kathy Katz; Jeanine Hatfield; Ana María Gómez; Hasan S Jafri; George H McCracken; Octavio Ramilo; Robert Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  In vivo efficacy of the ketolide ABT-773 (cethromycin) against enterococci in a mouse peritonitis model.

Authors:  Suresh R Pai; Kavindra V Singh; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

10.  Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.

Authors:  Charles M Fogarty; Tushar C Patel; Lala M Dunbar; Bruno P Leroy
Journal:  BMC Infect Dis       Date:  2005-05-31       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.